Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

NCT04321161 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia, in Relapse

Interventions

DRUG: Bicanorm

Sponsor

University of Freiburg